Skip to main content
. 2022 Mar 6;13(5):1623–1629. doi: 10.7150/jca.69415

Figure 4.

Figure 4

Survival analysis of LC patients between percentages of CD38+CD8+MAIT cell and PFS. The survival curve of low and high percentages from MAIT cell in the lung cancer patients across 320 days (A). The survival curve of low and high percentages from CD38+CD8+MAIT cell in the lung cancer patients across 320 days (B). P < 0.05 is regarded as significant.